Pharmacological Chaperones: Beyond Conformational Disorders

Author(s):  
Nancy J. Leidenheimer
2016 ◽  
Vol 52 (32) ◽  
pp. 5497-5515 ◽  
Author(s):  
Elena M. Sánchez-Fernández ◽  
José M. García Fernández ◽  
Carmen Ortiz Mellet

Recent advancements and future outlook on pharmacological chaperones for lysosomal storage disorders using glycomimetics are discussed.


2018 ◽  
Vol 8 (1) ◽  
Author(s):  
Graeme W. Carlile ◽  
Qi Yang ◽  
Elizabeth Matthes ◽  
Jie Liao ◽  
Stevo Radinovic ◽  
...  

2020 ◽  
Vol 27 (5) ◽  
pp. 622-634.e6 ◽  
Author(s):  
Prerana Ramadurgum ◽  
DaNae R. Woodard ◽  
Steffi Daniel ◽  
Hui Peng ◽  
Prema L. Mallipeddi ◽  
...  

Author(s):  
Yasmeena Akhter ◽  
Jahangir Nabi ◽  
Hinna Hamid ◽  
Nahida Tabassum ◽  
Faheem Hyder Pottoo ◽  
...  

Proteostasis is essential for regulating the integrity of the proteome. Disruption of proteostasis under some rigorous conditions leads to the aggregation and accumulation of misfolded toxic proteins, which plays a central role in the pathogenesis of protein conformational disorders. The protein quality control (PQC) system serves as a multi-level security system to shield cells from abnormal proteins. The intrinsic PQC systems maintaining proteostasis include the ubiquitin-proteasome system (UPS), chaperon-mediated autophagy (CMA), and autophagy-lysosome pathway (ALP) that serve to target misfolded proteins for unfolding, refolding, or degradation. Alterations of PQC systems in neurons have been implicated in the pathogenesis of various neurodegenerative disorders. This chapter provides an overview of PQC pathways to set a framework for discussion of the role of PQC in neurodegenerative disorders. Additionally, various pharmacological approaches targeting PQC are summarized.


Sign in / Sign up

Export Citation Format

Share Document